Loading...
In 1957, German pharmaceutical company Chemie Grünenthal launched thalidomide as a 'wonder drug' — a safe sedative that also relieved morning sickness. It seemed miraculous: unlike barbiturates, animal tests showed you couldn't take a lethal dose. By 1960, it was sold in 46 countries under dozens of brand names. Doctors prescribed it freely to pregnant women. In September 1960, the William S. Merrell Company applied to the FDA to sell thalidomide in the United States. The application landed on the desk of Frances Kelsey, a new medical officer just one month into her job. Merrell expected routine approval — the drug was already used across Europe, Canada, and Africa. Kelsey refused. She found the safety data inadequate. The application relied heavily on testimonials rather than controlle...
Popular framing: One stubborn FDA officer single-handedly saved American babies.
Structural analysis: Kelsey held the line, but what mattered structurally was that US regulation required margin-of-safety evidence the application couldn't supply, and her position carried decision rights immune to industry pressure. The disaster in 46 other countries surfaced the previously-invisible second-order risk (fetal effects), and the Kefauver-Harris Amendment converted the near-miss into a permanent system property: efficacy proof became prerequisite to approval everywhere afterward.
Focusing on individual heroism obscures that the US was saved by an institutional accident, not a reliable safeguard. Without encoding Kelsey's intuition into mandatory protocols — which Kefauver-Harris did — the same gap would have produced the same disaster with a less skeptical officer. The popular narrative celebrates the exception; the structural lesson is to eliminate dependence on exceptions.
